Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 901.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,504,219 shares of the company's stock after buying an additional 2,254,219 shares during the period. Jefferies Financial Group Inc. owned approximately 3.55% of Nkarta worth $6,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new position in shares of Nkarta in the fourth quarter valued at about $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta in the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Nkarta in the fourth quarter valued at about $37,000. ProShare Advisors LLC acquired a new position in shares of Nkarta in the fourth quarter valued at about $45,000. Finally, Catalina Capital Group LLC increased its holdings in shares of Nkarta by 57.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after purchasing an additional 6,867 shares during the period. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Stock Performance

Nkarta stock traded down $0.06 during midday trading on Friday, hitting $1.76. 337,231 shares of the company were exchanged, compared to its average volume of 1,061,944. The firm has a market capitalization of $124.53 million, a PE ratio of -0.93 and a beta of 0.81. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.23. The business has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $2.10.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. As a group, equities analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NKTX. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus cut their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 27th. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, Needham & Company LLC dropped their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $14.67.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.